Pliant's chronic liver disease drug has consistent safety across dose ranges, PhII data show - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
The highest dose of Pliant Therapeutics’ bexotegrast does not have improved activity over lower doses according to new biomarker data from a mid-stage primary sclerosing cholangitis (PSC) trial, but analysts say its consistent safety bodes well for the drug’s…